M05.A identifies rheumatoid arthritis in a patient with both a positive rheumatoid factor (RF) and positive anti-citrullinated protein antibody (ACPA/anti-CCP) on laboratory testing, representing dual-seropositive RA.
Verified May 8, 2026 · 4 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 5
- Region
- Multi-region
Documentation tips
What should appear in the chart to support M05.A.
Source · Editorial brief grounded in 4 cited references ↓
- Record both the RF result (titer or qualitative positive) and the anti-CCP/ACPA result with collection dates — dual positivity is what distinguishes M05.A from other M05 codes.
- If the affected joint is documented, code to the site-specific M05.0x–M05.8A code first and reserve M05.A for unspecified or multi-system encounters.
- Note that RA of the spine is excluded from M05 entirely — if spinal involvement is the reason for the visit, redirect to M45.-.
- Document whether the patient is on DMARDs or biologics; this supports medical necessity for ongoing management and differentiates active from monitored disease.
- Specify laterality for any peripheral joint involvement even if M05.A is the primary code, so that a site-specific code can be added as an additional diagnosis.
Related CPT procedures
Procedure codes commonly billed with M05.A. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M05.A and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Using M05.A as a default when a site-specific code (M05.00–M05.8A) is actually supported by the documentation — the Tabular 'Code First' instruction requires the site-specific code to lead when the joint is identified.
- Confusing M05.A with M06.0x (seronegative RA) or M05.9 (RF-positive RA, unspecified, without ACPA documentation) — M05.A requires explicit documentation of both RF positivity and ACPA/anti-CCP positivity.
- Assigning M05.A for juvenile patients — M08.- is mandatory for rheumatoid arthritis in patients under 16; M05.A is excluded for that population.
- Coding M05.A alongside M45.- for spinal RA — Type 1 Excludes prohibits concurrent use; spinal involvement routes entirely to M45.-.
Clinical context
Source · Editorial summary grounded in 4 cited references ↓
M05.A is the catch-all billable code within the M05 category for dual-seropositive rheumatoid arthritis when the specific joint site is not documented or when systemic/unspecified involvement is the focus of the encounter. The critical instruction from the Tabular List is to code first the site-specific RF-positive RA code (M05.00–M05.8A) if the affected joint is known — M05.A supplements or stands alone only when site specificity is absent from the documentation.
This code sits in the M05 block (Rheumatoid arthritis with rheumatoid factor), which carries a Type 1 Excludes for rheumatic fever (I00), juvenile rheumatoid arthritis (M08.-), and rheumatoid arthritis of the spine (M45.-). Do not use M05.A when any of those excluded conditions apply. If the patient has RA of the spine with RF and ACPA positivity, M45.- is the correct direction.
In an orthopedic or rheumatology context, M05.A is most relevant when labs confirm double-seropositivity (RF and anti-CCP both elevated) but the operative or clinic note fails to specify the exact joint involved, or when the encounter is focused on lab review and systemic disease management rather than a single anatomical site. Payers increasingly scrutinize RF-positive RA codes for supporting laboratory documentation — ensure the chart reflects the actual lab values and collection dates.
Sibling codes
Other billable codes under M05 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 4 cited references ↓
01What makes M05.A different from M05.9?
02When should I use M05.A versus a site-specific M05 code?
03Can M05.A be used for a pediatric RA patient?
04Is M05.A valid when RA primarily affects the spine?
05What lab documentation does the chart need to support M05.A at audit?
06Does M05.A require a 7th character?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (FY2026, effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M05-/M05.A
- 03unboundmedicine.comhttps://www.unboundmedicine.com/icd/view/ICD-10-CM/1432376/2/M05_A___Abnormal_rheumatoid_factor_and_anti_citrullinated_protein_antibody_with_rheumatoid_arthritis
- 04icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M05-
Mira Scribe
Mira AI Scribe captures the RF titer, anti-CCP/ACPA value, and lab draw dates directly from the encounter note to support M05.A. It also flags joint-specific language in the assessment — if a site is named, the scribe prompts for the more precise M05.0x–M05.8A code instead, preventing both undercoding and 'Code First' sequence errors that trigger claim edits.
See how Mira captures M05.A documentation